![Mary Lucus](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Mary Christine Lucus served as the Chief Financial Officer, Secretary & Controller at Selectis Health, Inc. from 2022 to 2023.
Prior to that, she worked as a Controller at NeuBase Therapeutics, Inc. Ms. Lucus received an undergraduate degree from San Diego State University.
Anciens postes connus de Mary Lucus
Sociétés | Poste | Fin |
---|---|---|
SELECTIS HEALTH, INC. | Directeur Financier/CFO | 05/04/2023 |
NEUBASE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | - |
Formation de Mary Lucus
San Diego State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
SELECTIS HEALTH, INC. | Finance |
Entreprise privées | 1 |
---|---|
NeuBase Therapeutics, Inc.
![]() NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on March 29, 2002 and is headquartered in Pittsburgh, PA. | Health Technology |